The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Single App knock-in mouse models of Alzheimer’s disease
Abstract
Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid β peptide (Aβ), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical Aβ pathology, neuroinflammation and memory impairment in an age-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We elected to use the AppNL-G-F knock-in mouse model for this study as it expresses App under its endogenous promoter in a physiological manner with regards to both cell type and amount, and avoids the issue of APP overexpression and abnormal expression patterns.”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“AppNL-G-F mice [C57BL/6-App<tm3(NL-G-F)Tcs> (No.RBRC06344)] were provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan [33].”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“we employed APPNLGF knock-in mice that express a humanized and triple-mutated APP in the endogenous App locus to circumvent transgenic mouse artifacts.”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [34]
In the citing paper
“While novel APP knock-in models, such as APPNL, APPNL-F, or APPNL-G-F mice overproduce Aβ1–42 in the absence of potentially confounding APP overexpression [139], these mice still contain one or more independent FAD mutations, which might result in an abnormal Aβ conformation [140].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [139]
In the citing paper
“By 6 months of age, App NL‐G‐F mice exhibit a substantial amyloid plaque burden in the brain”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“These were bred to the App NL‐G‐F AD‐like model to determine responses in the context of amyloid‐driven pathology (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F mice are characterized by progressive amyloid deposition from 2 months to cognitive decline by 6 months (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F knock‐in model, however, has physiological App expression levels, avoiding the overexpression artifacts found in other transgenic models”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“but is strongly biased toward very high Aβ42:40 ratios (~10–100:1) because of the familial mutations”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“In AppNL-G-F mice, which harbor all three mutations, Aβ amyloidosis is aggressive, and neuroinflammation is observed in subcortical structures as well as cortical regions [10–12].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“alternative mouse models have been generated via knock-in (KI) of a humanized Aβ sequences harboring familial AD mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) in order to model Aβ amyloidosis without non-physiological overexpression of APP [10].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“To overcome these issues, KI mouse models with familial AD mutations have been generated [10, 24, 31, 32].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“despite overproducing human Aβ40 and Aβ42 in their brains [10, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“These results are consistent with recent studies reporting negligible cognitive deficits and the lack of Aβ plaque formation in AppNL/NL mice (Fig. 6) [10, 11, 13, 14, 24].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“Both models express human APP at physiological levels.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Our result in female mice is consistent with the cognitive phenotype in the Y maze reported in this genotype25,42.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Human APP knockin (KI) models develop robust Aβ pathology, yet do not exhibit artifacts associated with APP over-expression, such as elevated levels of APP cleavage products (Saito et al., 2014).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These studies all suffer because they exhibit artifacts arising from the over-expression APP (WT or mutant) and in some cases mutant presenilins (Balducci and Forloni, 2011; Saito et al., 2014; Sasaguri et al., 2017).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“Human MAPT knock-in models have also been developed, and these models produce tau pathology, but only very late in the murine life span (~15 months) (Saito et al., 2014; Sakakibara et al., 2018; Sasaguri et al., 2022).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“However, over-expressing APP and presenilin 1 cause effect resulting from the over-expression that are unrelated to the disease process (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These mice develop robust plaque pathology beginning as early as 3 months of age, however they develop little tau pathology and little neurodegeneration (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These patterns of labeling or Aβ and MAPT are consistent with prior studies of APPNL-G-F and P301S MAPT mice (Yoshiyama et al., 2007; Saito et al., 2014; Sasaguri et al., 2017; Apicco et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“As expected,15 22-month-old AppNL-G-F mice had robust AD-related pathology, including amyloid deposition and neuroinflammation (Figures 1C and 1D).”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“As suggested,15,20 App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Humanized App knockin (KI) and APP transgenic mouse models mimic certain aspects of AD pathogenesis, including progressive amyloidosis, gliosis, and neuroinflammation, as well as network hyperexcitability and cognitive impairment, albeit to different degrees of severity across models and paradigms.15-27”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (Saito et al., 2014).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“By contrast, NHE6 ablation led to glial activation and decreased plaque load in ApoeAPOE4 (Sullivan et al., 1997) and AppNL-F (Saito et al., 2014) double knockin mice.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“The AppNL-F mouse model used in our study develops plaques at 12 months (Saito et al., 2014) in the presence of murine ApoE.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“In AppNL-F mice, plaques can be identified as early as 9 months of age.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (Saito et al., 2014) (own unpublished observations).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“We show in a well-studied App knock-in mouse model (Saito et al. , 2014) the gradual establishment of a multicellular co-expressed gene response encompassing 57 Plaque-Induced Genes or PIGs in the microenvironments of amyloid plaques (Figure 5).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“App NL-G-F knock-in (Saito et al., 2014) mice express Swedish (KM670/671NL), Beyreuther/Iberian (I716F), and Arctic (E693G) mutations in the App gene under the endogenous promoter on the C57Bl/6J background.”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“AD mice, in which APP with a humanised Aβ region containing 3 AD-related mutations (APPNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were crossed with NG2-DsRed mice in which pericytes express DsRed (19).”
From Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes (2019) · cites this paper as [49]
In the citing paper
“In contrast, knock-in of Swedish and Iberian mutations results in plaque development beginning at 6 months, and gliosis, synaptic alterations and memory impairment from 18 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“Additional knock-in of the Arctic mutation into these mice results in more rapid pathology development including plaque development beginning at 2 months that is more widespread throughout the brain and memory impairment from 6 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“In contrast, initial studies show that more physiological knock-in mouse models develop cognitive impairment many months after plaque development [129], which is more similar to humans.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Self-citationAβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459
Self-citationSarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,333
Animal Models of Alzheimer's Disease
Bharadwaj, P. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch10 · Cited by 3
Chemical Catalyst‐Mediated Selective Photo‐oxygenation of Pathogenic Amyloids
Sohma, Y., & Kanai, M. (2019) · Wiley eBooks · doi:10.1002/9783527344406.ch12 · Cited by 3
Salta, E., Walgrave, H., Balusu, S., Eynden, E. V., Snoeck, S., Craessaerts, K., Thrupp, N., Wolfs, L., Horré, K., Fourne, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.988709 · Cited by 3
Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic ImmunomodulationPreprint
Biechele, G., Blume, T., Deußing, M., Zott, B., Shi, Y., Xiang, X., Franzmeier, N., Kleinberger, G., Peters, F., Ochs, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.445761 · Cited by 3
Hori, Y., Sohma, Y., Kanai, M., & Tomita, T. (2022) · Neuroscience Insights · doi:10.1177/26331055221126179 · Cited by 3
Purro, S. A., Farmer, M., Quarterman, E., Ravey, J., Thomas, D. X., Noble, E., Turnbull, C., Linehan, J. M., Nazari, T., Brandner, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.11.602448 · Cited by 3
Trojan, E., Frydrych, J. K., Lasoń, W., & Basta‐Kaim, A. (2025) · Current Neuropharmacology · doi:10.2174/011570159x345385241004060055 · Cited by 2
Kaewsaen, R., Chanput, W. P., Rojanathammanee, L., Golovko, S. A., Seeger, D. R., Golovko, M. Y., Nookala, S., & Combs, C. K. (2025) · Nutrients · doi:10.3390/nu17101677 · Cited by 2
O’Niel, A., Parkins, C. J., Pederson, A., Saltonstall, E., Bunnell, E., Aggarwal, R., Sandholm, P., Kessler, K., Harrison, H. F., Smith, J. R., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1600119 · Cited by 2
Scharfman, H. E., Kam, K., Duffy, Á., LaFrancois, J. J., Leary, P., Chartampila, E., Ginsberg, S. D., & Lisgaras, C. P. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1513144 · Cited by 2
Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations
Varte, V., Ralte, L., & Kumar, N. S. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00203-y · Cited by 7
The impact of high-intensity interval training on cerebrovascular function in the APP/PS1 mice
Zhu, L., Cai, M., Lu, Z., Wang, Q., Zhai, T., & Hu, J. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1647628 · Cited by 2
White matters arising: Rethinking Alzheimer’s disease through the lens of myelin
Depp, C. (2025) · Science · doi:10.1126/science.aeb5153 · Cited by 3
Amyloid‐β Seeds in Alzheimer's Disease: Research Challenges and Implications
Beschörner, N., Xu, Y., Jucker, M., & Ruiz‐Riquelme, A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70267 · Cited by 2
Gentry, E., Islam, M. T., Xue, H., Cao, K., & Nemes, P. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101490 · Cited by 2
γ-Secretase exosites as targets for substrate-selective lowering of Aβ generation
Maruyama, R., Fukumori, A., Funamoto, S., Okada, K., Akamine, S., Yanagida, K., Shinohara, M., Sato, N., Okochi, M., Kudo, T., et al. (2025) · Structure · doi:10.1016/j.str.2025.11.010 · Cited by 2
Smith, V. L., Gidi, B. Z., Bragg, R. M., Cantle, J. P., Ben-Varon, A., Noble, B., Prades, S., Compton, A., Greenfield, J., Korecka, J. A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102815 · Cited by 2
Taguchi, J., Kikuchi, M., Jeon, H., Shimizu, R., Mori, H., Ikawa, M., Yamada, Y., Sato, K., Ikeda, T., Yamazaki, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67900-4 · Cited by 2
Aβ antibodies target not only amyloid plaques but also distinct brain cells and vessels
Wen, G., Lindblom, N., Zhan, X., Garcia, M. G., Deierborg, T., Kobro‐Flatmoen, A., & Gouras, G. K. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71121 · Cited by 2
Kano, M., 妙子, 木., Yanagisawa, H., Yamashita, K., Tatsumi, L., Sakai, A., Li, X., Saido, T. C., Saito, T., Takatori, S., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02407-7 · Cited by 2
Self-citationShipley, S., Abrate, M. P., Hayman, R. M. A., Chan, D., & Barry, C. (2026) · Current Biology · doi:10.1016/j.cub.2025.12.061 · Cited by 2
Kawade, N., Komine, O., Sobue, A., Kakimi, C., Tanaka, M., Suganami, T., Shimada, M., Ogi, T., Ikeda, K., Horiuchi, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-38129-y · Cited by 2
Self-citationMelgosa-Ecenarro, L., Radulescu, C. I., Doostdar, N., Airey, J., Chaloner, F. A., Zabouri, N., Pedretti, G., Osso, F., Perez, L. G., Pilch, K. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69866-3 · Cited by 4
Decoding the mechanisms of amyloid-β in synaptic toxicity
Toruński, P., Pizzirusso, G., Winblad, B. G., & Arroyo‐García, L. E. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424292 · Cited by 2
Poulot-Becq-Giraudon, Y., Guillemaud, O., Degl’Innocenti, E., Letenneur, V., Bascarane, K., Barbay, T., Clausen, M. M., Derbois, C., Guillermier, M., Juricek, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71826-w · Cited by 2
Svobodová, I., Bendová, Z., & Novotný, J. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin49765 · Cited by 2
Nicholson, L., Tang, S. J., Karra, T., Abouelatta, H., & Strittmatter, S. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00946-0 · Cited by 2
Houmam, S., Siodłak, D., Seshadri, M., Hallum, G. B., Pezant, N. P., Stanford, D. R., Salinas-Salinas, C., Thomason, Y. M., Santín-Márquez, R., Stout, M. B., et al. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150463 · Cited by 2
Klimmt, J., Gonçalves, C. C., Montgomery, J. V., Müller, S. A., Bublitz, M., Filser, S., Paeger, L., Nuscher, B., Dannert, A., Roeber, S., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02367-0 · Cited by 2
Astrocytic centrin‐2 expression in entorhinal cortex correlates with Alzheimer's disease severity
Degl’Innocenti, E., Poloni, T. E., Medici, V., Olimpico, F., Finamore, F., Profka, X., Bascarane, K., Morrone, C., Pastore, A., Escartin, C., et al. (2024) · Glia · doi:10.1002/glia.24603 · Cited by 2
Assessing cognitive flexibility in mice using a custom-built touchscreen chamber
Pais, R. C., Goldani, A., Hutchison, J., Mazrouei, A., Khavaninzadeh, M., Molina, L. A., Sutherland, R. J., & Mohajerani, M. H. (2025) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2025.1536458 · Cited by 3
Dujardin, P., Foroozandeh, J., Verhaegen, R., Burgelman, M., Nolf, C. D., Wonterghem, E. V., Imschoot, G. V., Peelaerts, W., Hochepied, T., Hoecke, L. V., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00027-y · Cited by 2
Biochemical and behavioural profile of NTBC treated Tyrosinemie type 1 mice
van Ginkel, W. G., Winn, S. R., Dudley, S., Krenik, D., Perez, R., Rimann, N., Thöny, B., Raber, J., & Harding, C. O. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.07.001 · Cited by 2
Romero‐Molina, C., Neuner, S. M., Ryszawiec, M., Pébay, A., Dominantly Inherited Alzheimer Network, Marcora, E. M., & Goate, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052565 · Cited by 3
Fagla, B. M., York, J. M., Christensen, A., Rosa, C. D., Balu, D., Pike, C. J., Tai, L. M., & Buhimschi, I. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-66489-w · Cited by 2
Ito, S., Iwata, Y., Otsuka, M., Kaneko, Y., Ogata, S., Yagi, R., Uemura, T., Masuda, T., Saito, T., Saido, T. C., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.051 · Cited by 2
Self-citationAlzheimer’s Disease from Modeling to Mechanism Research
Sun, X., & Zhang, W. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_7 · Cited by 2
Morito, T., Watamura, N., Sasaguri, H., Tomita, T., Higuchi, M., Okano, H., Sasaki, E., & Saido, T. C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251321116 · Cited by 2
Self-citationMaekawa, K., Sobue, A., Komine, O., Saito, Y., Murayama, S., Saido, T. C., Saito, T., & Yamanaka, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-98825-z · Cited by 4
Self-citationHigashi, Y., Ikuno, K., Saito, T., Saido, T. C., Miyasaka, T., Kakuda, N., & Funamoto, S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152025 · Cited by 2
Self-citationIzuo, N., Yokote, K., & Shimizu, T. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70093 · Cited by 2
The tale of donanemab: God is in the details
Saido, T. C., & Iwata, N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251371240 · Cited by 2
Self-citationDahlén, A. D., Roshanbin, S., Bucher, N. M., Sehlin, D., & Syvänen, S. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115475 · Cited by 2
Chen, W.-J., Wei, Y.-S., Lo, H., Chu, H.-F., Tseng, M., Lee, B., & Shen, T. (2024) · Journal of Food Biochemistry · doi:10.1155/2024/6676977 · Cited by 2
The Sound of Silence: Hidden Responses of Neural Circuits to Alzheimer-Linked Mutations
Atsmon, R., & Slutsky, I. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.016 · Cited by 2
Animal models of Alzheimer’s Disease
Morgan, D. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0053 · Cited by 2
Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves CognitionPreprint
Blume, T., Deußing, M., Biechele, G., Peters, F., Zott, B., Schmidt, C., Franzmeier, N., Wind-Mark, K., Eckenweber, F., Sacher, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.446348 · Cited by 2
Kohli, S., Andrianova, L., Margetts‐Smith, G., Brady, E. S., & Craig, M. T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.30.450500 · Cited by 2
Hossain, S. R., Karem, H., Jafari, Z., Kolb, B. E., & Mohajerani, M. H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.28.482233 · Cited by 2
The App NL-G-F mouse model of Alzheimer’s disease is refractory to regulatory T cell treatmentPreprint
Yshii, L., Mascali, L. G., Kouser, L., Lemaître, P., Marino, M., Dooley, J., Burton, O. T., Haughton, J., Callaerts‐Vegh, Z., Strooper, B. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.11.483903 · Cited by 4
A novel fully-automated system for lifelong continuous phenotyping of mouse cognition and behaviourPreprint
Ho, H., Kejzar, N., Sasaguri, H., Saito, T., Saido, T. C., Strooper, B. D., Bauža, M., & Krupic, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.18.496688 · Cited by 2
Self-citationGeneration of C9orf72 h370 mice, an intron 1 humanised C9orf72 repeat-expansion knock-in modelPreprint
Nair, R., Carcolé, M., Thompson, D., Tibbit, C., McLeod, R., Cammack, A. J., Jakubcova, T., Biggs, D., Wyles, M., Parker, M. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.06.636691 · Cited by 2
Tau conveys intrinsic hyperactivity of VTA dopamine neurons but an inability to sustain burst firingPreprint
Kennedy, W. M., Troyano‐Rodriguez, E., Higgs, M. H., Blankenship, H. E., Korukonda, A., Weinshenker, D., Rice, H. C., & Beckstead, M. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.28.666953 · Cited by 2
Dascenco, D., Marcassa, G., Mallopoulou, A., Vandensteen, J., LeFever, L. J., Leysen, E., Lorente-Echeverría, B., Koumoundourou, A., Daaboul, D., Ghesquière, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.24.689247 · Cited by 2
Distinct mechanistic pathways of early tauopathy revealed by MAPT mutationsPreprint
Foiani, M. S., Nirujogi, R., Watamura, N., Bez, S., Tsefou, E., Santambrogio, A., Patel, S., Hannah, D., Goulbourne, C. N., Fatima, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705716 · Cited by 2
Self-citationBevan, R. J., Maguire, E., Mackinnon, E., Salis, E., Phillips, T., Simonazzi, E., Vassileva, M., Allen, N. D., Williams, J., & Taylor, P. R. (2026) · Glia · doi:10.1002/glia.70192 · Cited by 1
(2022) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2022-096 · Cited by 1
Generation of sophisticated Alzheimer’s disease mouse models and research advances utilizing them
Hashimoto, S., & Saido, T. C. (2023) · Translational and Regulatory Sciences · doi:10.33611/trs.2023-003 · Cited by 1
Self-citationVarghese, R., Digholkar, G., Deshpande, A., & Kumar, D. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136142123010013 · Cited by 1
Simpson, D., Morrone, C. D., Wear, D., Gutierrez, J., & Yu, W. H. (2024) · Journal of Visualized Experiments · doi:10.3791/66792 · Cited by 1
Li, Q., Fu, Y., Cui, X.-J., Wang, Z.-T., Tan, L., & Initiative, A. D. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1339163 · Cited by 1
Age-related hearing loss: possible associations with Alzheimer’s disease
Ma, Y., Yang, Y., Zhou, Y.-F., Le, W., & Chai, R. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.24 · Cited by 1
Advancement in the animal model-based therapeutics in neurodegenerative diseases
Pal, D., Das, P., Ghosh, P., Gupta, S., Basak, P., & Nandi, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00007-0 · Cited by 1
Ageing in animals: Alzheimer’s like disease
Kutwad, S., Khankal, S., & Prabhu, A. (2025) · Next research. · doi:10.1016/j.nexres.2025.101076 · Cited by 1
Emery, B. A., Khanzada, S., Hu, X., Maggi, M. A., Bisti, S., & Amin, H. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11253272 · Cited by 1
Böck, D., Tidecks, L., Wilhelm, M., ElGrawani, W., Duss, S. N., Trevisan, C., Vena, D. L., Reuss, A. M., Kissling, L., Ranucci, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65964-w · Cited by 1
Park, J., Kim, B.-G., Ha, M., Park, M., Ryu, H., Yu, H., Park, S. S., Roh, Y., Lim, K., Hong, J. T., et al. (2025) · Advanced Science · doi:10.1002/advs.202503725 · Cited by 2
Su, X., Takayanagi, R., Maeda, H., Saido, T. C., & Ohshima, T. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00799-0 · Cited by 1
Self-citationC3 lowering in adult APP KI mice rescues synapses and spares cognitive decline
Singh, B. B., Batista, A. F., Spooner, E. T., Colletti, B. R., Saido, T. C., Carroll, M. C., & Lemere, C. A. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00009-6 · Cited by 1
Self-citationAraki, K., Yamauchi, K., Ito, S., Koike, M., & Hioki, H. (2026) · Anatomical Science International · doi:10.1007/s12565-025-00915-5 · Cited by 1
Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition
Han, J., Jeong, J., Lee, D., Jung, Y., Jin, Y., Jung, E. S., Kim, H. J., Kim, W. Y., Lee, C., & Mook‐Jung, I. (2026) · Advanced Science · doi:10.1002/advs.202513135 · Cited by 1
Takayanagi, R., Matsunaga, H., Wei, R., Sugeno, A., 粟倩雅, Ochi, T., Saido, T. C., Takeyama, H., & Ohshima, T. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100219 · Cited by 1
Self-citationDecoding Alzheimer's Disease One Cell Class at a Time
Darvas, M., Cook, D. G., & Scimemi, A. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01685-y · Cited by 1
Milicevic, K. D., Abreu, A. C., Chandran, G., Zhu, Y. M. D., Hu, X., Ivanova, V. O., Jami, M., Simon, B., Fernández, I., Yan, R., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47370-4 · Cited by 1
Izuo, N., Kondoh, H., & Shimizu, T. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70483 · Cited by 1
Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s disease
Nakagawa, T., Xie, J. L., Park, K., Cao, K., Savadkohighodjanaki, M., Zhang, Y. J., Jun, H., Ichii, A., Lee, J. Y., Soma, S., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02260-w · Cited by 2
Self-citationGera, R., Mocci, G., Tambaro, S., Vanlandewijck, M., Nilsson, P., Eriksdotter, M., & Mitra, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1722477 · Cited by 1
Self-citationHirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
Gonzalez, M. M., Magondu, B., Rowan, M. J., & Forest, C. R. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.05.005 · Cited by 1
Animal models of Alzheimer’s disease and related disorders
Saido, T. C. (2026) · Neuroscience Research · doi:10.1016/j.neures.2026.105069 · Cited by 1
Self-citationSudo, Y., Sung, C.-J., Nakayoshi, R., Kobayashi, H., Kikuchi, K., Chiu, Y., Takatori, S., Hori, Y., & Tomita, T. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00034-z · Cited by 1
Boyanova, S., Katsouri, L., Krupic, J., Hair, K., Wang, S., & Wiseman, F. K. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104633 · Cited by 1
Tung, T.-H., Babu, S., Tang, X., Sciutto, A. L., Romer, M. A., Racha, P., 徐, R. 榕. X., Fiesler, V. M., Saha, A., Thai, T., et al. (2026) · Brain · doi:10.1093/brain/awag234 · Cited by 1
Self-citationZeng, C. (2026) · Neurology International · doi:10.3390/neurolint18070139 · Cited by 1
Cruz-Sesé, J., Miron-Alcala, M., Alfonso-Triguero, M., Olalde, J., Ruiz, L., Galbis-Gramage, N., Cortés, L., Escobar, L., Preman, P., Snellinx, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117803 · Cited by 1
Self-citationFibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease
Bhattarai, P., Yılmaz, E., Cakir, E. Ö., Tayran, H., Haq, I., Murphy, D., Keller, J. N., Grand, Q. L., Eschbach, J., Çelikkaya, H., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01204-0 · Cited by 1
Chronic Neuroinflammation Underlying Pathogenesis of Alzheimer’s Disease
Saito, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-56068-5_50 · Cited by 1
Self-citationNieraad, H., de Bruin, N. M. W. J., Arne, O., Hofmann, M. C. J., Pannwitz, N., Resch, E., Luckhardt, S., Schneider, A., Trautmann, S., Schreiber, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.876826 · Cited by 1
Development and application of animal behavior analysis system using video images
SAKAMOTO, N., Miyazaki, Y., Kobayashi, K., & Murata, T. (2022) · Translational and Regulatory Sciences · doi:10.33611/trs.2022-002 · Cited by 1
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis
Jiang, R., Smailović, U., Haytural, H., Haret, R. M., Shevchenko, G., Tijms, B. M., Gobom, J., Abelein, A., Johansson, J., Zetterberg, H., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.054474 · Cited by 1
Self-citationNeuroinflammation and neuroimmunology in Alzheimer's disease
Yamanaka, K. (2023) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12750 · Cited by 2
Rico, E. M. G., Joseph, P., Noutsos, C., & Poon, K. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.007 · Cited by 1
Akasaka, T., Watanabe, H., & Ono, M. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00525 · Cited by 1
Rodriguez, G. A., Aoun, A., Rothenberg, E. F., Shetler, O., Posani, L., Vajram, S. V., Tedesco, T. G., Sharma, A., Fusi, S., & Hussaini, S. A. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117505 · Cited by 2
Catabolism and Anabolism of Amyloid-β
Hashimoto, S., Nilsson, P., & Saido, T. C. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_19 · Cited by 2
Self-citationAnimal models of Alzheimer’s disease
Saito, A., & Saido, T. C. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.144.250 · Cited by 1
Self-citationAlzheimer’s Disease and Mechanism-Based Attempts to Enhance Cognition
Draffin, J. E., Knafo, S., & Heneka, M. T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00009-7 · Cited by 1
Targets and Strategies Toward the Development of Alzheimer Therapeutics
Wolfe, M. S. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_14 · Cited by 2
Neuroinflammation in dementia and neurodegeneration
Yamanaka, K. (2018) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12478 · Cited by 1
Spinazzi, E. F., Upadhyayula, P. S., & McKhann, G. M. (2019) · Neurosurgery · doi:10.1093/neuros/nyz035 · Cited by 1
Metadata
- Authors
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C.
- Affiliations
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Saido, Takaomi C
- Venue
- Nature Neuroscience
- Published
- 2014-04-13
- Volume
- 17
- Issue
- 5
- Pages
- 661-663
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2090620788
- Cited by
- 1,366
- References
- 26
- Citations by year
- 2026: 159 · 2025: 164 · 2024: 209 · 2023: 167 · 2022: 157 · 2021: 155 · 2020: 92 · 2019: 73 · 2018: 64 · 2017: 49 · 2016: 37 · 2015: 24 · 2014: 13
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23680039, 26290019)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, knock-in mice, amyloid precursor protein, APP mutations, Swedish mutation, Arctic mutation, amyloid-beta pathology, neuroinflammation, memory impairment, age-dependent phenotype
- MeSH terms
- Age Factors, Alzheimer Disease, Analysis of Variance, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Maze Learning, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
